Totus | Category

News & Media /

Press Releases

Totus Medicines

PRESS RELEASES 05.06.2026

Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026

Totus Medicines

PRESS RELEASES 04.30.2026

Totus Medicines to Present Interim Phase 1b Clinical Data for TOS-358 + Fulvestrant Doublet Therapy in HR+/HER- Breast Cancer Patients at ESMO Breast Cancer Annual Congress 2026

Totus Medicines

PRESS RELEASES 04.16.2026

Totus Medicines to Present First-in-Class Covalent IRF5 Inhibitor Data at AAI IMMUNOLOGY2026

Totus Medicines

PRESS RELEASES 03.18.2026

Totus Medicines Presents Phase 1a Clinical Data for TOS-358, a Covalent PI3Ka Inhibitor, at ESMO TAT 2026

Totus Medicines

PRESS RELEASES 02.12.2026

Totus Medicines to Present Updated Phase 1 Clinical Data for TOS-358 at ESMO Targeted Anticancer Therapies Congress 2026

Jp morgan healthcare conference 2026 locumpedia events calendar

PRESS RELEASES 01.06.2026

Totus Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

Simon Harnest

PRESS RELEASES 01.27.2025

Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

Zelanna Goldberg

PRESS RELEASES 01.10.2025

Totus Medicines Announces Successful Completion of a Phase 1 Dose-Escalation Study and Initiation of an Expansion Trial Evaluating TOS-358 and Appoints Zelanna Goldberg as Chief Medical Officer

Totus Lilly

PRESS RELEASES 05.16.2024

Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly